Receptor-binding domain as a target for developing SARS vaccines
Identifieur interne : 001668 ( Pmc/Curation ); précédent : 001667; suivant : 001669Receptor-binding domain as a target for developing SARS vaccines
Auteurs : Xiaojie Zhu [République populaire de Chine] ; Qi Liu [République populaire de Chine] ; Lanying Du [États-Unis] ; Lu Lu [République populaire de Chine] ; Shibo Jiang [République populaire de Chine, États-Unis]Source :
- Journal of Thoracic Disease [ 2072-1439 ] ; 2013.
Abstract
A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.
Url:
DOI: 10.3978/j.issn.2072-1439.2013.06.06
PubMed: 23977435
PubMed Central: 3747534
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001668
Links to Exploration step
PMC:3747534Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Receptor-binding domain as a target for developing SARS vaccines</title><author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali</wicri:regionArea></affiliation></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="1"><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23977435</idno><idno type="pmc">3747534</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747534</idno><idno type="RBID">PMC:3747534</idno><idno type="doi">10.3978/j.issn.2072-1439.2013.06.06</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">001668</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001668</idno><idno type="wicri:Area/Pmc/Curation">001668</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001668</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Receptor-binding domain as a target for developing SARS vaccines</title><author><name sortKey="Zhu, Xiaojie" sort="Zhu, Xiaojie" uniqKey="Zhu X" first="Xiaojie" last="Zhu">Xiaojie Zhu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali</wicri:regionArea></affiliation></author><author><name sortKey="Du, Lanying" sort="Du, Lanying" uniqKey="Du L" first="Lanying" last="Du">Lanying Du</name><affiliation wicri:level="1"><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:regionArea></affiliation></author><author><name sortKey="Lu, Lu" sort="Lu, Lu" uniqKey="Lu L" first="Lu" last="Lu">Lu Lu</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name><affiliation wicri:level="1"><nlm:aff id="aff1">Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</nlm:aff><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai</wicri:regionArea></affiliation><affiliation wicri:level="1"><nlm:aff id="aff2">Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Lindsley F. Kimball Research Institute, New York Blood Center, New York</wicri:regionArea></affiliation></author></analytic><series><title level="j">Journal of Thoracic Disease</title><idno type="ISSN">2072-1439</idno><idno type="eISSN">2077-6624</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.</p></div></front></TEI><pmc article-type="review-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">J Thorac Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Thorac Dis</journal-id><journal-id journal-id-type="publisher-id">JTD</journal-id><journal-title-group><journal-title>Journal of Thoracic Disease</journal-title></journal-title-group><issn pub-type="ppub">2072-1439</issn><issn pub-type="epub">2077-6624</issn><publisher><publisher-name>Pioneer Bioscience Publishing Company</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23977435</article-id><article-id pub-id-type="pmc">3747534</article-id><article-id pub-id-type="publisher-id">jtd-05-S2-S142</article-id><article-id pub-id-type="doi">10.3978/j.issn.2072-1439.2013.06.06</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Receptor-binding domain as a target for developing SARS vaccines</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Xiaojie</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Qi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Lanying</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Lu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jiang</surname><given-names>Shibo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff id="aff1"><label>1</label>Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Medical College and Institute of Medical Microbiology, Fudan University, Shanghai, China;</aff><aff id="aff2"><label>2</label>Lindsley F. Kimball Research Institute, New York Blood Center, New York, USA;</aff><aff id="aff3"><label>3</label>Department of Medical Microbiology and Immunology, School of Basic Medicine, Dali University, Dali, China</aff></contrib-group><author-notes><corresp id="cor1">Corresponding to: Shibo Jiang. 130 Dong An Road, Building #13, Xuhui District, Shanghai 200032, China. Email: <email xlink:href="shibojiang@fudan.edu.cn">shibojiang@fudan.edu.cn</email>.</corresp></author-notes><pub-date pub-type="epub-ppub"><month>8</month><year>2013</year></pub-date><pmc-comment>Fake ppub date generated by PMC from publisher
pub-date/@pub-type='epub-ppub' </pmc-comment>
<pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><volume>5</volume><issue>Suppl 2</issue><fpage>S142</fpage><lpage>S148</lpage><history><date date-type="received"><day>16</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>06</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>2013 Pioneer Bioscience Publishing Company. All rights reserved.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Pioneer Bioscience Publishing Company.</copyright-holder></permissions><abstract><p>A decade ago, severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a global pandemic with a mortality rate of 10%. Reports of recent outbreaks of a SARS-like disease caused by Middle East respiratory syndrome coronavirus (MERS-CoV) have raised serious concerns of a possible reemergence of SARS-CoV, either by laboratory escape or the presence of a natural reservoir. Therefore, the development of effective and safe SARS vaccines is still needed. Based on our previous studies, we believe that the receptor-binding domain (RBD) in the S1 subunit of the SARS-CoV spike (S) protein is the most important target for developing a SARS vaccine. In particular, RBD of S protein contains the critical neutralizing domain (CND), which is able to induce highly potent neutralizing antibody response and cross-protection against divergent SARS-CoV strains. Furthermore, a RBD-based subunit vaccine is expected to be safer than other vaccines that may induce Th2-type immunopathology. This review will discuss key advances in the development of RBD-based SARS vaccines and the possibility of using a similar strategy to develop vaccines against MERS-CoV.</p></abstract><kwd-group kwd-group-type="author"><title>KEY WORDS </title><kwd>Virus</kwd><kwd>severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV)</kwd><kwd>receptor-binding domain (RBD)</kwd><kwd>spike protein</kwd><kwd>vaccine</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001668 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 001668 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Curation
|type= RBID
|clé= PMC:3747534
|texte= Receptor-binding domain as a target for developing SARS vaccines
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i -Sk "pubmed:23977435" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |